Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance.
A recent study, showing the absence of paroxysmal nocturnal hemoglobinuria clones in myelofibrosis, has reopened the debate around the role of decreased haptoglobin in this disease. We present here a large prospective analysis of the clinical significance of low haptoglobin in 152 patients with myelofibrosis. Low haptoglobin (<32mg/dL) was observed in 50 patients (33%). Decreased haptoglobin did not associate with low hemoglobin levels, positive Coombs test or abnormal liver function tests, suggesting it is not result of autoimmune hemolytic anemia or liver cirrhosis. Factors strongly correlating with decreased haptoglobin were high JAK2 allele burden and ongoing treatment with JAKi. Larger scale serial measurement and longer follow-up is needed to further explain our findings.
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Paolo
P
Strati
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Lucia
L
Masarova
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Prithviraj
P
Bose
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Naval
N
Daver
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Naveen
N
Pemmaraju
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: sverstov@mdanderson.org.
Srdan
S
Verstovsek
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D005260:Female; D006242:Haptoglobins / Q000032:analysis* / Q000172:deficiency; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000097:blood*; D011446:Prospective Studies; D055815:Young Adult
D006242:Haptoglobins; C507924:JAK2 protein, human; D053614:Janus Kinase 2
Haptoglobin; JAK inhibitors; JAK2; Myelofibrosis